Interestingly, according to single-cell sequencing analysis of CRPC cell lines37, TDO2 was significantly overexpressed in a more advanced drug-resistant CRPC cell subpopulation (Fig. 3c; Supplementary Fig. S10a), suggesting that TDO2 mRNA is persistently expressed in the late stage of prostate cancer. The gene discussed is TDO2; the disease is prostate carcinoma.